Fulgent Genetics (NASDAQ:FLGT – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday, Zacks.com reports. The firm currently has a $65.00 price target on the stock. Zacks Investment Research‘s price objective indicates a potential upside of 18.20% from the stock’s current price.
According to Zacks, “Fulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information. The Company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to hospitals and medical institutions. Fulgent Genetics, Inc. is headquartered in Temple City, California. “
Several other research firms have also recently weighed in on FLGT. Oppenheimer decreased their target price on Fulgent Genetics from $141.00 to $125.00 and set an “outperform” rating for the company in a research note on Tuesday, January 25th. StockNews.com began coverage on Fulgent Genetics in a research note on Thursday, March 31st. They set a “hold” rating for the company. Finally, Piper Sandler boosted their target price on Fulgent Genetics from $80.00 to $85.00 in a research note on Tuesday, March 1st.
Fulgent Genetics (NASDAQ:FLGT – Get Rating) last announced its quarterly earnings data on Wednesday, February 23rd. The company reported $3.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.66 by $0.68. The business had revenue of $251.67 million during the quarter, compared to analysts’ expectations of $191.10 million. Fulgent Genetics had a return on equity of 51.21% and a net margin of 51.12%. The business’s quarterly revenue was down 14.7% compared to the same quarter last year. During the same quarter last year, the business posted $6.12 EPS. On average, analysts anticipate that Fulgent Genetics will post 7.3 EPS for the current year.
In other Fulgent Genetics news, CFO Paul Kim sold 454 shares of the business’s stock in a transaction that occurred on Thursday, March 3rd. The stock was sold at an average price of $56.31, for a total value of $25,564.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 29.50% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of FLGT. Spire Wealth Management increased its holdings in shares of Fulgent Genetics by 10.8% in the fourth quarter. Spire Wealth Management now owns 1,375 shares of the company’s stock valued at $138,000 after purchasing an additional 134 shares during the period. Raymond James Financial Services Advisors Inc. increased its holdings in shares of Fulgent Genetics by 0.7% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 20,322 shares of the company’s stock valued at $1,828,000 after purchasing an additional 146 shares during the period. Maryland State Retirement & Pension System increased its holdings in shares of Fulgent Genetics by 2.4% in the fourth quarter. Maryland State Retirement & Pension System now owns 7,730 shares of the company’s stock valued at $778,000 after purchasing an additional 180 shares during the period. First Foundation Advisors increased its holdings in shares of Fulgent Genetics by 4.0% in the third quarter. First Foundation Advisors now owns 4,728 shares of the company’s stock valued at $425,000 after purchasing an additional 182 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Fulgent Genetics by 3.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 5,527 shares of the company’s stock valued at $556,000 after purchasing an additional 182 shares during the period. Institutional investors own 38.33% of the company’s stock.
About Fulgent Genetics (Get Rating)
Fulgent Genetics, Inc, together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests.
- Get a free copy of the StockNews.com research report on Fulgent Genetics (FLGT)
- Simpson Manufacturing Co. Hits The Nail On The Head, Again
- The Sherwin-Williams Company Bottoms Above Institutional Support
- What To Make Of Activision Blizzard (NASDAQ: ATVI)
- Whirlpool Is A Steal At These Prices
- Kimberly-Clark Pops On Successful Price Pass-Through
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.